Prognostic immune markers in non-small cell lung cancer

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5247-5256

  Suzuki, Kei ^a   Kachala, Stefan S ^a   Kadota, Kyuichi ^a,b   Shen, Ronglai ^a   Mo, Qianxing ^a   Beer, David G ^c   Rusch, Valerie W ^a   Travis, William D ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD14 ANTIGEN; CD15 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD59 ANTIGEN; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; OSTEOGENIC PROTEIN 1; PROSTAGLANDIN E2; PROTEIN S 100; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; BLOOD SAMPLING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; GENE CLUSTER; GENE FUNCTION; HUMAN; IMMUNE RESPONSE GENE; IMMUNOCOMPETENT CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MACROPHAGE; MICROARRAY ANALYSIS; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; LUNG NEOPLASMS; MODELS, GENETIC; MODELS, IMMUNOLOGICAL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 80051688291     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2805     Document Type: Review

References (69)

1. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-2666 (Pubitemid 41817714)
2. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213 (Pubitemid 36077915)
3. Shedden K, Taylor JMG, Enkemann SA, Tsao M-S, Yeatman TJ, Gerald WL, et al. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-827
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964 (Pubitemid 44498003)
5. Kataki A, Scheid P, Piet M, Marie B, Martinet N, Martinet Y, et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002;140:320-328 (Pubitemid 35302024)
6. Mori M, Ohtani H, Naito Y, Sagawa M, Sato M, Fujimura S, et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 2000;191:113-118
7. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, et al. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000;27:27-35.
8. Trojan A, Urosevic M, Dummer R, Giger R, Weder W, Stahel RA. Immune activation status of CD8+ T cells infiltrating non-small cell lung cancer. Lung Cancer 2004;44:143-147 (Pubitemid 38482046)
9. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006;94:275-280 (Pubitemid 43151547)
10. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007;98:1424-1430 (Pubitemid 47243535)
11. Cosio MG, Majo J, Cosio MG. Inflammation of the airways and lung parenchyma in COPD: role of T cells. Chest 2002;121[Suppl]:160S-165S (Pubitemid 34497335)
12. Grumelli S, Corry DB, Song L-Z, Song L, Green L, Huh J, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med 2004;1:e8.
13. Robbins CS, Bauer CMT, Vujicic N, Gaschler GJ, Lichty BD, Brown EG, et al. Cigarette smoke impacts immune inflammatory responses to influenza in mice. Am J Respir Crit Care Med 2006;174:1342-1351 (Pubitemid 44913036)
14. Kalra R, Singh SP, Savage SM, Finch GL, Sopori ML. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000;293:166-171 (Pubitemid 30180936)
15. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macrì L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009;87:365-371, discussion 371-2.
16. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003;94:1003-1009 (Pubitemid 37521216)
17. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14:5220-5227
18. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Can J Surg 2001;44:180-188 (Pubitemid 32538769)
19. Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008;26:4410-4417
20. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010;5:585-590
21. Sharma S, Yang S-C, Zhu L, Reckamp K, Gardner B, Baratelli F, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-5220 (Pubitemid 40827331)
22. Mutter R, Lu B, Carbone DP, Csiki I, Moretti L, Johnson DH, et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res 2009;15:2158-2165
23. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-2872 (Pubitemid 44937041)
24. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-237
25. Chen JJW, Yao P-L, Yuan A, Hong T-M, Shun C-T, Kuo M-L, et al. Upregulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003;9:729-737 (Pubitemid 36182607)
26. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007;30:627-632 (Pubitemid 351194821)
27. Ho C-C, Liao W-Y, Wang C-Y, Lu Y-H, Huang H-Y, Chen H-Y, et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 2008;177:763-770 (Pubitemid 351490563)
28. Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer 2008;98:1118-1124 (Pubitemid 351399802)
29. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005;23:8959-8967 (Pubitemid 46211481)
30. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78 (Pubitemid 38082155)
31. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumorassociated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-322 (Pubitemid 44922352)
32. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009;33:118-126
33. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010;5:1507-1515
34. Fridlender ZG, Jing S, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 2009;16:183-194
35. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009;137:425-428
36. Okita R, Saeki T, Takashima S, Yamaguchi Y, Toge T. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncol Rep 2005;14:1269-1273
37. Li L, Chao QG, Ping LZ, Xue C, Xia ZY, Qian D, et al. The prevalence of FOXP3 +regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm 2009;24:357-367
38. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, et al. PGE (2) contributes to TGF-b induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2010;2:356-367
39. De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000;117:365-373 (Pubitemid 30111584)
40. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005;175:4583-4592 (Pubitemid 41361997)
41. Liu C-Y, Wang Y-M, Wang C-L, Feng P-H, Ko H-W, Liu Y-H, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33 +myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35-45.
42. Bryant CM, Albertus DL, Kima S, Guedj M, Travis WD, Yatabe Y, et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways. PLOS 2010;5:e11712.
43. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 2009;106:2824-2828
44. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009;27:2793-2799
45. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15:284-290
46. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008;3:e1651.
47. Lee ESSD, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-7404
48. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu C-Q, Strumpf D, et al. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci U S A 2008;105:10155-10160
49. Raz DJ, Ray MR, Kim JY, He B, Taron M, Skrzypski M, et al. A multigene assay is prognostic of survival in patients with earlystage lung adenocarcinoma. Clin Cancer Res 2008;14:5565-5570
50. Larsen JE, Pavey SJ, Passmore LH, Bowman RV, Hayward NK, Fong KM. Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res 2007;13:2946-2954 (Pubitemid 46849569)
51. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007;117:3436-3444 (Pubitemid 350096999)
52. Chen H-Y, Yu S-L, Chen C-H, Chang G-C, Chen C-Y, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20. (Pubitemid 46041749)
53. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu C-Q, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-5569
54. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-5090 (Pubitemid 46631412)
55. Lu Y, Lemon W, Liu P-Y, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 2006;3:e467.
56. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA. Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 2005;172:729-737 (Pubitemid 41324228)
57. Beer DG, Kardia SLR, Huang C-C, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-824
58. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE 2010;5:e10312.
59. Dieu M-C, Vanbervliet B, Vicari A, Bridon J-M, Oldham E, Aït-Yahia S, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998;188:373-386 (Pubitemid 28357765)
60. Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, et al. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000;60:2209-2217 (Pubitemid 30225185)
61. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer 2003;105:186-189 (Pubitemid 36505319)
62. Hillinger S, Yang S-C, Zhu L, Huang M, Duckett R, Atianzar K, et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 2003;171:6457-6465 (Pubitemid 37532074)
63. Hillinger S, Yang SC, Batra RK, Strieter RM, Weder W, Dubinett SM, et al. CCL19 reduces tumour burden in a model of advanced lung cancer. Br J Cancer 2006;94:1029-1034
64. Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, et al. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells. Mol Cancer 2003;2:35.
65. Lee JM, Garon EB, Baratelli F, Schaue D, Pak PS, Wallace WD, et al. Phase I trial of CCL21 gene modified dendritic cells in non-small cell lung cancer. J Clin Oncol 2010;28:TPS157.
66. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
67. Ming J, Zhang Q, Qiu X, Wang E. Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer. Eur J Cancer 2009;45:866-873
68. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-1198 (Pubitemid 37540688)
69. Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, et al. CD4+CXCR4highCD69 +T cells accumulate in lung adenocarcinoma. J Immunol 2006;177:6983-6990